Author:
Asngari Nurul Jannah Mohd,Bakar Khairul Azreena,Feroz Shevin Rizal,Razak Fathilah Abdul,Halim Adyani Azizah Abd
Subject
Organic Chemistry,Biochemistry,Biophysics
Reference59 articles.
1. Effects of odanacatib on bone structure and quality in postmenopausal women with osteoporosis: 5-year data from the phase 3 long-term odanacatib fracture trial (LOFT) and its extension;Recker;J. Bone Miner. Res.,2020
2. Odanacatib, A cathepsin K-specific inhibitor, inhibits inflammation and bone loss caused by periodontal diseases;Hao;J. Periodontol.,2015
3. A small molecule, odanacatib, inhibits inflammation and bone loss caused by endodontic disease;Hao;Infect. Immun.,2015
4. Merck & Co. drops osteoporosis drug odanacatib;Mullard;Nat. Rev. Drug Discov.,2016
5. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT extension study;McClung;Lancet Diabet. Endocrinol.,2019
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献